In short: In Terranova's insurer list (12:31) — the same higher-rates-for-longer beneficiary.
In short: Not recommended, though he "wouldn't disagree" it is the best commercial P&C company: it carries more large-account business, "the stuff that ends up facing kind of the most competition" in a soft market, and its reserves impress him less than Travelers'. ~2x book, a bit expensive.
Chubb is widely seen as the best commercial insurer, and Tunis doesn't argue. He just thinks it has more exposure to insuring very large companies — the segment where competition bites hardest as prices fall — and less of a reserve cushion than Travelers, at a similar price.
26:07Travelers footprint. Chubb has I don't want to take away from Chubb. they have a you know a
26:13good-size business there as well but
In short: The fourth insurer in Brown's list of names he's been highlighting all year whose charts "look great" — the AI-adopter margin story rather than an AI-supplier story.
In short: His third insurance momentum name (with Allstate and Travelers) — evidence the momentum factor has spread into reasonable-valuation financials, not just growth.
Chubb is one of the world's largest property-and-casualty insurers. Terranova names it third (with Allstate and Travelers) to drive home that insurance has been a quiet momentum sector in 2026 — strong performance, sensible valuations — the kind of "reasonable-valuation" momentum he wants alongside the flashier tech.
In short: Valuation comp only — trades ~12.3× NTM earnings / ~1.64x P/B, a premium to Travelers despite TRV's higher 22.7% core ROE. Chubb's international diversification and high-net-worth brand partly explain its multiple. Cited to frame the TRV discount, not an argued call on CB.
Nothing matches this filter.
Verbatim excerpts from the public transcripts (auto-pulled at each mention's timestamp, lightly cleaned). Timestamps link into the video; "source page" opens that commentator's full analysis at this row. Click a mention's header line to expand it (one open at a time). For personal study — not investment advice.